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Dengue is the most important arboviral disease worldwide, since 50% of the
population in the world live in 125 countries where the disease is endemic (50-200
million infections/year, 20.000 deaths/year)[1]. This disease is caused by 4 serotypes of
Dengue virus (DENV-1 to DENV-4) and it is transmitted to humans in tropical and
subtropical countries by mosquito bites from the Aedes genus [2]. There are different
kinds of clinical manifestations of the infection: asymptomatic disease, soft -
nonspecific disease, classic feverish disease or severe disease (Dengue Haemorragic
Fever – DHF – and Dengue Shock Syndrome – DSS -) [3].
INTRODUCTION
• Multiple hit  phenomenon (Neutralization).
•Antibody-mediated enhancement of infection, 
ADE (Enhancement).
The immune response is a key
factor against the infection. 
- Innate immunity: first barrier (INF 
production). 
It brings either neutralization or enhancement  of 
the infectivity of DENV:
• Original antigenic sin 
(Enhancement).
• Massive production of cytokines 
and immunomodulators
Today, a Dengue vaccine is thought to be the most important preventive strategy in the future. The ideal
vaccine should produce homotypic and heterotypic immune responses for all the serotypes. There are some
challenges to achieve a good vaccine, being the ADE phenomenon the most important to overcome [4, 5, 6].
VACCINES
Live Attenuated Vaccine[2, 5, 6]
Targeted Mutagenesis Live
Atenuated Vaccine [2, 5, 6, 7]
Chimeric Virus Vaccine [2, 5, 6, 8]
Inactivated Virus Vaccine [5, 9]
Virus Subunit Vaccine [5, 10, 11]
DNA Vaccine [5, 6] Virus Like Particles Vaccine [12]
Virus – Vectored Vaccine [5, 6]
CONCLUSIONS
- DENV is attenuated through
serial tissue culture passages. It
induces adaptative immune
responses against structural and
non-structural proteins of the
virus  Most similar to induced
natural immunity.
• Walter Reed Army Research
Institute (WRAIR)  Phase II.
• Mahidol University 
(Bangkok).
-Targeted mutagenesis to
attenuate DENV  Δ30 dNTPs
in 3’-UTR of cDNA. Clones of
DENV-4 and DENV-1 showed
optimal immunogenicity;
DENV-2 and DENV-3 non-
functional (under-attenuation).
• Use of DENV-4Δ30 as a
genetic backbone for serotypes
2 and 3.
• Mutation in E protein (E-
Glu345K) of DENV-4/ DENV-
4Δ30.
-Specific protein encoding genes
substitution of one virus for
those of another.
• ChimeriVax Dengue 
Tetravalent Vaccine (CVD1-4) 
 DENV wt - Yellow Fever 
Virus 17D chimera (prM and E 
proteins). Phase II.
• DENVax DENV-2 
backbone – prM and E proteins 
DENV-1, 3, 4 chimera. Phase I.
-Multiple Vero cells culture
passages of DENV and formalin
inactivation once they are
purified.
• TDENV PIV  Phase I
(WRAIR).
- Structural proteins or domains
produced in expression systems
 Domain III of E protein
(EDIII).
• r80E Truncated 
recombinant protein (20% protein 
removal at C-terminal). Phase I.
•LcEDIII Lipidated EDIII 
consensus (DENV-1 to DENV-4), 
without adjuvants.
•DIIIC-2 DENV-2 EDIII – C 
protein fusion , with adjuvants.
•Tet-EDIII – Co1 constructions 
 Oral vaccine project.
-Encoding antigenic genes
cloned into a plasmid vector,
inducing a protective cytotoxic
immune response.
- Low efficiency: difficulty for
exogenous DNA to enter the
host cells.
• WRAIR  prM and E
encoding genes. With adjuvants.
• NS1 an encoding gene 
NS1 induces specific serotype
immune responses.
- Use of different viruses as
expression vectors of DENV
genes, resulting in the
expression of its antigenic
proteins  Virus Replicon
Particles (VRP).
• cAdVax-DenTV
Adenovirus (vector) – DENV 
prM/E proteins construction. 
Pre-clinical phase.
- Spherical membrane vesicles
containing prM/E proteins
embedded in a lipid bilayer,
with or without a nucleocapsid
 Virion imitation.
- There are still factors to be
understood (in vivo and in vitro
different results).
- Adaptive immunity: 6 days after the bite. 
Dengue is a worldwide health problem and vaccination is considered as the future ideal strategy to solve it. There are still some
factors of the disease to be understood in order to find an efficient vaccine that does not enhance the disease or cause critical side
effects. However, the positive results obtained in research are making feasible the Dengue vaccine as the solution to reduce the
burden of the disease in the future.
(Enhancement).[2, 4]
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